Literature DB >> 19309490

Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival.

Amy Frey1, Ayman O Soubani, Abdulgadir K Adam, Shijie Sheng, Harvey I Pass, Fulvio Lonardo.   

Abstract

AIMS: To evaluate whether there is a correlation between the subcellular localization of maspin and the histological, molecular and biological features of pulmonary adenocarcinoma, particularly addressing the hypothesis that the tumour inhibitor properties of maspin may be linked to a nuclear, compared with a combined nuclear and cytoplasmic expression pattern. METHODS AND
RESULTS: The subcellular expression of maspin was determined in 80 resected pulmonary adenocarcinomas (Stage I, 46; Stage II, 10; Stage III, 20; Stage IV, 4) and correlated with histological grade, proliferative rate, p53 expression, vascular endothelial growth factor (VEGF)-A levels, and prognosis (mean follow-up of 41.5 months). Cases with nuclear (N) maspin (n = 47), compared with the [N + cytoplasmic (C)] group (n = 28), showed lower (P <or= 0.05): histological grade, proliferative rate, p53 expression and VEGF-A levels. Cox multivariate analysis revealed in stage I adenocarcinomas (N) maspin as the only predictor of improved survival.
CONCLUSIONS: (N) maspin selects lung adenocarcinomas with distinct molecular and clinical features, supporting the hypothesis that its tumour inhibitor properties may be linked to its nuclear localization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19309490      PMCID: PMC2911575          DOI: 10.1111/j.1365-2559.2009.03260.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  35 in total

1.  Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis.

Authors:  N Maass; T Hojo; F Rösel; T Ikeda; W Jonat; K Nagasaki
Journal:  Clin Biochem       Date:  2001-06       Impact factor: 3.281

2.  Evidence for the epidermal growth factor receptor as a target for lung cancer prevention.

Authors:  Fulvio Lonardo; Konstantin H Dragnev; Sarah J Freemantle; Yan Ma; Natalie Memoli; David Sekula; Elisabeth A Knauth; Jean S Beebe; Ethan Dmitrovsky
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

3.  Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis.

Authors:  H Han; J F Silverman; T S Santucci; R S Macherey; T A d'Amato; M Y Tung; R J Weyant; R J Landreneau
Journal:  Ann Surg Oncol       Date:  2001 Jan-Feb       Impact factor: 5.344

4.  Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast.

Authors:  N Maass; M Teffner; F Rösel; R Pawaresch; W Jonat; K Nagasaki; P Rudolph
Journal:  J Pathol       Date:  2001-10       Impact factor: 7.996

5.  The paradoxical expression of maspin in ovarian carcinoma.

Authors:  Anil K Sood; Mavis S Fletcher; Lynn M Gruman; Jeremy E Coffin; Sarvenaz Jabbari; Zhila Khalkhali-Ellis; Nancy Arbour; Elisabeth A Seftor; Mary J C Hendrix
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

Review 6.  Regulation of tumor suppressors by nuclear-cytoplasmic shuttling.

Authors:  Megan Fabbro; Beric R Henderson
Journal:  Exp Cell Res       Date:  2003-01-15       Impact factor: 3.905

7.  Expression of maspin predicts poor prognosis in breast-cancer patients.

Authors:  Yoshihisa Umekita; Yasuyo Ohi; Yoshiatsu Sagara; Hiroki Yoshida
Journal:  Int J Cancer       Date:  2002-08-01       Impact factor: 7.396

Review 8.  Bevacizumab in the treatment of non-small-cell lung cancer.

Authors:  T E Stinchcombe; M A Socinski
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 9.867

9.  Maspin expression in invasive breast cancer: association with other prognostic factors.

Authors:  Syed K Mohsin; Ming Zhang; Gary M Clark; D Craig Allred
Journal:  J Pathol       Date:  2003-04       Impact factor: 7.996

10.  Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomas.

Authors:  I Bièche; I Girault; J-C Sabourin; S Tozlu; K Driouch; M Vidaud; R Lidereau
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

View more
  14 in total

Review 1.  The natural tumor suppressor protein maspin and potential application in non small cell lung cancer.

Authors:  Fulvio Lonardo; Xiaohua Li; Alexander Kaplun; Ayman Soubani; Seema Sethi; Shirish Gadgeel; Shijie Sheng
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

2.  Maspin modulates adhesion of bladder carcinoma cells to vascular endothelium.

Authors:  Eva Juengel; Wolf-Dietrich C Beecken; Santhosh Mundiyanapurath; Tobias Engl; Dietger Jonas; Roman A Blaheta
Journal:  World J Urol       Date:  2010-03-25       Impact factor: 4.226

3.  HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.

Authors:  Xiaohua Li; Alexander Kaplun; Fulvio Lonardo; Elisabeth Heath; Fazlul H Sarkar; Jonathan Irish; Wael Sakr; Shijie Sheng
Journal:  Mol Cancer Res       Date:  2011-05-26       Impact factor: 5.852

4.  Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters.

Authors:  Ahmet Bircan; Sema Bircan; Nilgun Kapucuoglu; Necla Songur; Onder Ozturk; Ahmet Akkaya
Journal:  Pathol Oncol Res       Date:  2010-03-28       Impact factor: 3.201

5.  Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression.

Authors:  Gayatri Sharma; Sameer Mirza; Rajinder Parshad; Anurag Srivastava; Siddartha Datta Gupta; Pranav Pandya; Ranju Ralhan
Journal:  Tumour Biol       Date:  2010-08-10

6.  High frequency of coexpression of maspin with p63 and p53 in squamous cell carcinoma but not in adenocarcinoma of the lung.

Authors:  Bonnie Choy; Jennifer J Findeis-Hosey; Faqian Li; Loralee A McMahon; Qi Yang; Haodong Xu
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

7.  Maspin expression in prostate tumor elicits host anti-tumor immunity.

Authors:  Sijana H Dzinic; Kang Chen; Archana Thakur; Alexander Kaplun; R Daniel Bonfil; Xiaohua Li; Jason Liu; M Margarida Bernardo; Allen Saliganan; Jessica B Back; Hiroshi Yano; Dana L Schalk; Elyse N Tomaszewski; Ahmed S Beydoun; Gregory Dyson; Adelina Mujagic; David Krass; Ivory Dean; Qing-Sheng Mi; Elisabeth Heath; Wael Sakr; Lawrence G Lum; Shijie Sheng
Journal:  Oncotarget       Date:  2014-11-30

8.  Elevated maspin expression is associated with better overall survival in esophageal squamous cell carcinoma (ESCC).

Authors:  Yang Wang; Shijie Sheng; Jianzhi Zhang; Sijana Dzinic; Shaolei Li; Fang Fang; Nan Wu; Qingfeng Zheng; Yue Yang
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

9.  Role of maspin in cancer.

Authors:  Rossana Berardi; Francesca Morgese; Azzurra Onofri; Paola Mazzanti; Mirco Pistelli; Zelmira Ballatore; Agnese Savini; Mariagrazia De Lisa; Miriam Caramanti; Silvia Rinaldi; Silvia Pagliaretta; Matteo Santoni; Chiara Pierantoni; Stefano Cascinu
Journal:  Clin Transl Med       Date:  2013-03-07

10.  Identification of an intrinsic determinant critical for maspin subcellular localization and function.

Authors:  Sijana H Dzinic; Alexander Kaplun; Xiaohua Li; Margarida Bernardo; Yonghong Meng; Ivory Dean; David Krass; Paul Stemmer; Namhee Shin; Fulvio Lonardo; Shijie Sheng
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.